Trial Profile

A Phase 1/2 Open-Label, Multicenter, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of BH-30643 in Subjects with Locally Advanced or Metastatic NSCLC Harboring EGFR And/or HER2 Mutations (SOLARA)

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 28 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

22 Jan 2025 According to the BlossomHill Therapeutics Media Release, first cohort of patients has been dosed in this study. and Additional details on the design and discovery of BH-30643 will be reported at an upcoming medical meeting.
06 Jan 2025 Planned initiation date changed from 2 Dec 2024 to 1 Jan 2025.
29 Nov 2024 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com